Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Celldex: Update Based on 2Q, 2016 Conference Call (CLDX, Neutral, $4.45)

Investment View

Celldex has a broad array of clinical trials underway or in planning that involve five drugs. However, most of…
Read more…

Celldex: ACT IV Trial of Rintega in Newly Diagnosed Glioblastoma has Been Terminated (CLDX, Hold, $4.01)

ACT-IV Trial is Halted

The independent Data Safety and Monitoring Board (DSMB) just completed its second interim review of the phase…
Read more…

Celldex: Meaningful Data on Two Lead Products, Rintega and glembatumumab, is not Likely Before 2017 (CLDX, Hold, $16.99)

Key Points;

The big news of the 2Q, 2015 conference call was that the FDA has discouraged Celldex from filing an…
Read more…

Comments on Agenus, Neuralstem and Celldex

SmithOnStocks Mailbox
About the Mailbox:
My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

Celldex Pipeline Update and Investment Thesis (CLDX, Moving from Buy to Hold, $28.56)

Overview
This report updates my investment thinking on Celldex and also provides a brief overview of its two late stage products.…
Read more…

SmithOnStocks Mailbox, January 31 Edition: My Take on News Events Relating to Companies I Follow

Introduction

A number of subscribers have suggested that I write more on recent news events that relate to companies that I…
Read more…

Immuno-Oncology Promises to be the Next “Big Thing” In Biotechnology

Immuno-Oncology Promises to be the Next “Big Thing” In Biotechnology
Purpose of the Report

Immuno-oncology has been the hottest area in biotechnology…
Read more…

Celldex, Moving to A Buy (CLDX, $14.16)

Investment Thesis

Celldex held a conference call after the close on Friday, November 14, 2014 to discuss the interim results of…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Celldex: I View the Recent Data on Rindopepimut as Encouraging (CLDX, Hold, $22.52) (Subscribers Only)

Report Overview
Celldex released interim data on the ReACT trial of rindopepimut in recurrent glioblastoma at the Society for Neuro-Oncology (SNO)…
Read more…

Celldex: Equity Offering is a Positive for the Stock (CLDX, Hold, $25.88)

Celldex (CLDX) has just announced a financing in which the Company has issued 7.0 million shares and will receive net…
Read more…

Celldex Stay Tuned for Monday’s Conference Call on Rindopepimut (CLDX, Hold, $28.31)

Investment Significance of Upcoming Conference Call
Celldex (CLDX) has raised expectations for positive results for rindopepimut in recurrent glioblastoma. It will…
Read more…

Celldex (CLDX, $23.06): Previewing the Imminent Data Release on Rindopepimut

Note: Comprehensive reports are now available to paid subscribers and can be found in the Reports section.

Investment Background and Thesis
This post is the…
Read more…

Celldex (CLDX, $23.06): Previewing the Imminent Data Release on Rindopepimut

Investment Background and Thesis
In my initial report on Celldex, I highlighted four interesting products that the Company has in development.…
Read more…

Celldex: Why Investors Are So Excited About the Company (CLDX, Hold, $24.39)

This post is an excerpt from the report: Celldex: Pipeline Promise Has Been Embraced by Wall Street

Comprehensive reports are now available…
Read more…

Celldex Initiation Report: Pipeline Promise Has Been Embraced by Wall Street (CLDX, Hold, $22.79)

Review of Amazing and Volatile Stock Price Performance
From the closing price on December 30, 2011 through October 1, 2013 Celldex’s…
Read more…